A major analysis of more than 1.2 million medical records has found popular diabetes and weight loss drugs, including Ozempic and Wegovy, may also reduce the risk of other health issues.

Veru said Monday that its investigational drug helped preserve lean mass in patients taking the obesity treatment Wegovy, though some experts were skeptical that the topline results were adequate ...

Novo Nordisk’s breakneck sales growth has continued in the first quarter of this year with a 24% increase that was helped by a doubling in turnover of obesity blockbuster Wegovy. Group revenues ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy alone but investors await more data. Veru Inc. on Monday unveiled topline ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.